Rival to IVF 'is safer and cheaper'

Rival to IVF 'is safer and cheaper'

Women who have difficulty conceiving will be able to benefit from a new method of IVF that is cheaper and safer than conventional fertility treatments, doctors say.

Clinical trials in Denmark have shown that a pioneering technique known as in-vitro maturation (IVM) has a success rate of 30 per cent, comparable to standard IVF procedures. The patient, however, does not have to take expensive fertility drugs that can carry serious side-effects.

With conventional IVF doctors stimulate the release of mature eggs using hormone drugs and collect them during a woman’s monthly cycle before fertilising them in the laboratory with a man’s sperm.

The IVM method involves taking undeveloped eggs from ovaries and maturing them in the laboratory before fertilisation, while using hardly any drugs or no drugs at all.

More than 400 healthy babies have so far been born to women using the technique, which could reduce the cost of fertility treatment by up to half and give thousands more women the chance to conceive.

Professor Svend Lindenberg, a Danish scientist who has helped more than 1,000 women become pregnant using IVM, told a London fertility conference that the process had now achieved “stunning results”.

“We have demonstrated that it is possible to take an egg and fertilise it without having to use the heavy-duty drug approach,” he said. “We are achieving results that are better than nature and as good as high-stimulation IVF, without the risk of potentially life-threatening ovarian hyperstimulation and, of course, saving thousands of pounds per cycle in the cost of drugs.”

Professor Lindenberg, who works at the Nordica Fertility Centre in Copenhagen, explained: “We give a very low dose of a stimulating drug for three days early in the cycle and rescue up to ten eggs. For the first 24 hours a tiny amount of stimulating hormone is added to the culture, in fact one hundreth of the dose the woman would receive, and after that the eggs go on to mature in the culture alone.”

Under present IVF methods many women have been reluctant to donate their eggs for IVF because the drugs they must take can lead to life-threatening complications and an increased risk of cancer.

The demand for donor eggs is huge — potential recipients outnumber donors by two to one in Britain. In Denmark the move to IVM has been driven by women who are reluctant to take drugs, often because the problem lies with the male partner and not themselves, Professor Lindenberg said.

The technique is not suitable for all women; it works best in those who are under 37 years of age, have regular cycles or polycystic ovary syndrome, where women frequently fail to ovulate naturally. “This is part of a worldwide move against high-dose stimulation IVF,” Professor Lindenberg said. There was now no excuse to continue giving women high dosages of stimulation to the detriment of their health and their financial and emotional wellbeing.

IVM has previously been successful in creating animal embryos but the process has only recently been tried on human eggs. It was originally developed by Bob Edwards who, with Patrick Steptoe, were resposible for Louise Brown, the world’s first IVF baby.

It has been made easier by the development of finer needles to aspirate the eggs from an ovary and new scanning techniques that now show doctors the best follicles to select when seeking eggs to remove.